Blood cancer drug sabatolimab gets Long-Term safety check
NCT ID NCT05201066
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study follows people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from the drug sabatolimab in an earlier trial. The goal is to collect more safety information over time, not to test a new treatment. About 33 participants will continue taking sabatolimab as long as their doctor thinks it helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute Univ of Utah
Salt Lake City, Utah, 84112 0550, United States
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Florianópolis, Santa Catarina, 88020-210, Brazil
-
Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9, Canada
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Alexandroupoli, 681 00, Greece
-
Novartis Investigative Site
Pátrai, 265 04, Greece
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Fukushima, 960 1295, Japan
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.